Alzheimer’s disease

Sep 02, 2025

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly 360 mg subcutaneous autoinjector designed for maintenance do...

Aug 13, 2025

Over the past decade, big data in healthcare has evolved from a promising concept into a transformative force reshaping patient care, clinical research, and hospital operations. What began as fragmented data stored in electronic health records has now expanded into massive, interconnected datasets drawn from wearab...

Jul 22, 2025

Sarepta Therapeutics Pauses ELEVIDYS Shipments in U.S. After FDA Intervention Over Patient Deaths Sarepta Therapeutics, Inc. has voluntarily and temporarily paused all shipments of ELEVIDYS (delandistrogene moxeparvovec) in the U.S., effective July 22, 2025, following engagement with the FDA on safety labeling u...

Apr 25, 2025

The 77th Annual Meeting of the American Academy of Neurology (AAN 2025), held from April 5–9 in San Diego and online, served as a pivotal forum for advancing research in neurology, with particular relevance to neurodegenerative diseases. As one of the largest gatherings of neurologists globally, the conference prov...

Apr 18, 2025

The Alzheimer's and Parkinson's Diseases (AD/PD) 2025 International Conference, conducted in April in Vienna, Austria, and online, stands as a pivotal event in neurodegenerative disease research. This hybrid gathering brings together global experts to delve into the latest advancements in Alzheimer’s and Parkinson’...

Apr 08, 2025

Amgen’s UPLIZNA Becomes First FDA-Approved Treatment for IgG4-Related Disease Amgen announced that the FDA has approved UPLIZNA (inebilizumab-cdon) as the first and only treatment for adults with Immunoglobulin G4-related disease (IgG4-RD), a rare and chronic immune-mediated inflammatory condition that can affec...

Feb 26, 2025

Alzheimer’s disease remains one of the most complex and devastating neurodegenerative disorders, affecting millions worldwide and placing an immense burden on patients, caregivers, and healthcare systems. Characterized by progressive cognitive decline, memory loss, and functional impairment, Alzheimer’s disease cur...

Feb 12, 2025

Alzheimer’s disease is a devastating neurodegenerative disorder that affects millions worldwide, progressively impairing memory, cognitive function, and independence. Despite extensive research, current Alzheimer’s disease drugs provide only limited relief, and there remains no cure. With the number of cases projec...

Feb 12, 2025

Alzheimer’s, the most common type of dementia, particularly with an increasing geriatric population, presents a major global crisis. The disease mostly occurs in sexagenarians, but it may manifest in quadragenarians. It is one of the most prevalent neurodegenerative disorders with a multifactorial pathogenesis. It ...

Feb 12, 2025

Alzheimer’s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer's drug market...